| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Serum SEMA4A levels were markedly elevated in patients with eosinophilic chronic rhinosinusitis (ECRS) and asthma patients. Moreover, SEMA4A was strongly expressed in eosinophils in both nasal polyps and eosinophils in peripheral blood. Consistent with these results, bone marrow derived eosinophils from SEMA4A-deficient mice showed shorter survival and less activation than those from wild type mice.
Conclusion: These results suggest that SEMA4A potentially exacerbate Th2 inflammation through promoting eosinophil survival and activation and can be a marker for discriminating specific endotype in ECRS and asthma.
|
